neuralized E3 ubiquitin protein ligase 3Genealiases: LINCR · RNF132
Q-omics provides the consensus-scored NEURL3 profile across patient tissues and cancer cell-line models. NEURL3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NEURL3 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, NEURL3 RNA expression shows 14,804 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KICH, and UVM as cancer lineages where NEURL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEURL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEURL3 survival associations across molecular data types. NEURL3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEURL3 RNA expression–survival associations across cancer types. High NEURL3 expression shows unfavorable associations in LIHC, THYM and UVM, but favorable associations in SKCM, BLCA and STAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for NEURL3 RNA expression.
This table summarizes NEURL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NEURL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEURL3 shows lower tumor expression in KICH, BRCA and KIRC and higher tumor expression in STAD, UCEC and LIHC. The KICH box plot shows higher NEURL3 RNA expression in normal versus tumor tissue (log2 FC = −2.710, t-test p < 0.001).
This table shows molecular features associated with NEURL3 in patient tissues and cancer cell lines. In patient samples, NEURL3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NEURL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
